Vanda Pharmaceuticals: Here’s What Investors Need to Know Before Earnings

Vanda Pharmaceuticals (NASDAQ:VNDA) will report earnings before markets open on Thursday, May 9th. Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of clinical-stage, small molecule product candidates for central nervous system disorders.

Here is your Cheat Sheet to Vanda Pharmaceuticals Earnings:

Earnings Expectations: Analysts expect earnings of $-0.25 per share on revenues of $8.41 million.

Analyst Trends:

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.11 to a loss $0.25. For the current year, the average estimate is a loss of $0.89, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Vanda Pharmaceuticals has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 0.00 4.55 35.71 31.27 32.73
Diluted EPS ($) -1.92 -1.33 0.25 -0.35 -0.98

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 8.37 8.14 8.38 8.29 7.92
Diluted EPS ($) -0.1965 -0.28 -0.28 -0.19 -0.2256

Past Performance:
Vanda Pharmaceuticals has missed analyst estimates 3 times in the past four quarters. Shareholders could expect a bust if the company misses estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]